Ewing sarcoma program (CancerVAX/University of California Los Angeles)

N/A

Report date: 2025/03/20 15:48:59

Base Information

Drug NameEwing sarcoma program (CancerVAX/University of California Los Angeles)

Drug Alias NameN/A

ClassificationVaccinesBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsSarcoma, Ewing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesCancervax Co University Of California, Los Angeles

Inactive CompaniesN/A

Active IndicationsSarcoma, Ewing

Inactive IndicationsN/A

Other Information

ATC CodeN/A